Disease-modifying strategies for Parkinson's disease

Movement Disorders

Volumn 30, Issue 11, 2015, Pages 1442-1450

  Kalia, Lorraine V ^a,b,c,d   Kalia, Suneil K ^d,e   Lang, Anthony E ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autophagy; Gene therapy; LRRK2; Mitochondria; Neuroprotection

Indexed keywords

ACETYLCYSTEINE; ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; CAFFEINE; CREATINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; ISRADIPINE; NEURTURIN; NICOTINE; PIOGLITAZONE; PLACEBO; PRAMIPEXOLE; SARGRAMOSTIM; UBIDECARENONE; ANTIPARKINSON AGENT;

ACTIVE IMMUNIZATION; ADENO ASSOCIATED VIRUS 2; ADIPOSE DERIVED STEM CELL; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); PARKINSON DISEASE; PASSIVE IMMUNIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT PLANNING; ANIMAL; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENETICS; METABOLISM; PROCEDURES;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HUMANS; PARKINSON DISEASE;

EID: 84941598760     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26354     Document Type: Review

References (63)

1. AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2014;11:6-23.
2. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; doi:10.1016/S0140-6736(14)61393-3
3. Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-408.
4. Marks WJ, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
5. Bartus RT, Herzog CD, Chu Y, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011;26:27-36.
6. Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80:1698-1701.
7. Olanow CW, Bartus RT, Baumann T, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson's disease: a double-blind, randomized, controlled trial. Ann Neurol 2015; doi: 10.1002/ana.24436.
8. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S39-S47.
9. Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 2014;71:543-552.
10. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 2015;313:584-593.
11. Gu M, Iravani MM, Irvani M, et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004;91:1075-1081.
12. Iravani MM, Haddon CO, Cooper JM, et al. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006;96:1315-1321.
13. Iravani MM, Sadeghian M, Leung CCM, et al. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol 2008;212:522-531.
14. Schapira AH, McDermott MP, Barone P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013;12:747-755.
15. Fox SH, Katzenschlager R, Lim S-Y, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-S41.
16. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015; doi: 10.1016/S1474-4422(15)00144-1
17. Kalia LV, Kalia SK, McLean PJ, et al. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol 2013;73:155-169.
18. Visanji NP, Brooks PL, Hazrati L-N, et al. The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun 2013;1:2.
19. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012;72:893-901.
20. Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79:651-658.
21. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
22. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-466.
23. Decressac M, Kadkhodaei B, Mattsson B, et al. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 2012;4:163ra156.
24. Gong L, Zhang Q-L, Zhang N, et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway. J Neurochem 2012;123:876-885.
25. Chen X, Burdett TC, Desjardins CA, et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc Natl Acad Sci U S A 2013;110:300-305.
26. Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep 2012;12:367-375.
27. Schwarzschild MA, Ascherio A, Beal MF, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71:141-150.
28. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 2012;288:10736-10741.
29. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 2011;43:364-371.
30. Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013;28:1823-1831.
31. Ritz B, Lee P-C, Lassen CF, et al. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 2014;83:1396-1402.
32. Aviles-Olmos I, Limousin P, Lees A, et al. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013;136:374-384.
33. Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123:2730-2736.
34. Martin HL, Teismann P. Glutathione: a review on its role and significance in Parkinson's disease. FASEB J 2009;23:3263-3272.
35. Wu G, Lu Z-H, Kulkarni N, et al. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J Neurosci Res 2012;90:1997-2008.
36. Wu G, Lu Z-H, Kulkarni N, et al. Mice lacking major brain gangliosides develop parkinsonism. Neurochem Res 2011;36:1706-1714.
37. Schneider JS, Gollomp SM, Sendek S, et al. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J Neurol Sci 2013;324:140-148.
38. Lindström V, Fagerqvist T, Nordström E, et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol Dis 2014;69:134-143.
39. Tran HT, Chung CH-Y, Iba M, et al. α-Synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep 2014;7:2054-2065.
40. Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol 2013;125:795-813.
41. Fonseca-Ornelas L, Eisbach SE, Paulat M, et al. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation. Nat Commun 2014;5:5857.
42. Cooper JM, Wiklander PBO, Nordin JZ, et al. Systemic exosomal siRNA delivery reduced α-synuclein aggregates in brains of transgenic mice. Mov Disord 2014;29:1476-1485.
43. Decressac M, Mattsson B, Weikop P, et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci 2013;110:E1817-E1826.
44. Steele JW, Ju S, Lachenmayer ML, et al. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol Psychiatry 2013;18:882-888.
45. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46:989-993.
46. Marras C, Schüle B, Schuele B, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011;77:325-333.
47. Kethiri RR, Bakthavatchalam R. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011-2013). Expert Opin Ther Pat 2014;24:745-757.
48. West AB. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord 2015;30:180-189.
49. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
50. Fuji RN, Flagella M, Baca M, et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med 2015;7:273ra15.
51. Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson's disease. Mov Disord. 2013;28:725-732.
52. Schapansky J, Nardozzi JD, Felizia F, et al. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet. 2014;23:4201-4214.
53. Renna M1, Jimenez-Sanchez M, Sarkar S, et al. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem 2010;285:11061-11067.
54. Fan X, Jin WY, Lu J, et al. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014;17:471-480.
55. Ruzza P, Siligardi G, Hussain R, et al. Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro. ACS Chem Neurosci 2014;5:30-38.
56. Chotibut T, Davis RW, Arnold JC, et al. Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model. Mol Neurobiol 2014;49:1282-1292.
57. Ho S-C, Hsu C-C, Pawlak CR, et al. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model. Behav Brain Res 2014;268:177-184.
58. Paumier KL, Siderowf AD, Auinger P, et al. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Mov Disord 2012;27:880-887.
59. Paumier KL, Sortwell CE, Madhavan L, et al. Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system. Exp Neurol 2015;266:11-21.
60. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012;209:975-986.
61. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-953.
62. Sacino AN, Brooks M, McGarvey NH, et al. Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein. Acta Neuropathol Commun 2013;1:38.
63. Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014;75:351-362.